New Delhi, May 1 -- Sparking criticism and raising concerns, British-Swedish multinational pharmaceutical firm AstraZeneca has for the first time acknowledged in court documents in the UK that its Covid-19 vaccine, which is known as Covishield in India, has the potential to cause Thrombosis with Thrombocytopenia Syndrome (TTS), a rare side effect associated with blood clotting.

This condition involves the formation of blood clots accompanied by a low platelet count, which is critical for blood clotting. As per media reports in the UK, the pharma giant is facing up to 51 litigations, being sued in class action over claims its vaccine caused death and serious injury in dozens of cases. In India, it was one of the widely administered Covid ...